22nd Century Gross Margin 2011-2024 | XXII
Current and historical gross margin for 22nd Century (XXII) over the last 10 years. The current gross profit margin for 22nd Century as of June 30, 2024 is %.
22nd Century Gross Margin Historical Data |
Date |
TTM Revenue |
TTM Gross Profit |
Gross Margin |
2024-06-30 |
$0.03B |
$-0.01B |
-27.59% |
2024-03-31 |
$0.03B |
$-0.01B |
-34.48% |
2023-12-31 |
$0.03B |
$-0.01B |
-28.13% |
2023-09-30 |
$0.03B |
$-0.00B |
-9.09% |
2023-06-30 |
$0.03B |
0 |
0.00% |
2023-03-31 |
$0.04B |
$0.00B |
5.00% |
2022-12-31 |
$0.04B |
$0.00B |
5.00% |
2022-09-30 |
$0.05B |
$0.00B |
4.00% |
2022-06-30 |
$0.04B |
$0.00B |
2.56% |
2022-03-31 |
$0.03B |
0 |
0.00% |
2021-12-31 |
$0.03B |
$0.00B |
3.23% |
2021-09-30 |
$0.03B |
$0.00B |
6.67% |
2021-06-30 |
$0.03B |
$0.00B |
6.90% |
2021-03-31 |
$0.03B |
$0.00B |
7.41% |
2020-12-31 |
$0.03B |
$0.00B |
3.70% |
2020-09-30 |
$0.03B |
0 |
0.00% |
2020-06-30 |
$0.03B |
0 |
0.00% |
2020-03-31 |
$0.03B |
0 |
0.00% |
2019-12-31 |
$0.03B |
0 |
0.00% |
2019-09-30 |
$0.03B |
$0.00B |
4.00% |
2019-06-30 |
$0.03B |
$0.00B |
4.00% |
2019-03-31 |
$0.03B |
$0.00B |
3.85% |
2018-12-31 |
$0.03B |
$0.00B |
3.85% |
2018-09-30 |
$0.03B |
0 |
0.00% |
2018-06-30 |
$0.02B |
0 |
0.00% |
2018-03-31 |
$0.02B |
0 |
0.00% |
2017-12-31 |
$0.02B |
0 |
0.00% |
2017-09-30 |
$0.01B |
0 |
0.00% |
2017-06-30 |
$0.01B |
0 |
0.00% |
2017-03-31 |
$0.01B |
0 |
0.00% |
2016-12-31 |
$0.01B |
0 |
0.00% |
2016-09-30 |
$0.01B |
0 |
0.00% |
2016-06-30 |
$0.01B |
0 |
0.00% |
2016-03-31 |
$0.01B |
0 |
0.00% |
2015-12-31 |
$0.01B |
0 |
0.00% |
2015-09-30 |
$0.01B |
0 |
0.00% |
2015-06-30 |
$0.00B |
0 |
0.00% |
2015-03-31 |
$0.00B |
0 |
0.00% |
2014-12-31 |
$0.00B |
0 |
nan% |
2014-09-30 |
$0.01B |
$0.01B |
100.00% |
2014-06-30 |
$0.01B |
$0.01B |
100.00% |
2013-09-30 |
$0.00B |
0 |
nan% |
2012-09-30 |
$0.00B |
0 |
nan% |
2011-12-31 |
$0.00B |
0 |
0.00% |
Sector |
Industry |
Market Cap |
Revenue |
Consumer Staples |
Tobacco Products |
$0.003B |
$0.032B |
22nd Century Group, Inc. is a plant biotechnology company focused on decreasing/increasing the level of nicotine in the tobacco plant through genetic engineering and breeding. The Company is focused on development of smoking cessation aid and owns and controls several patents. The company's products include X-22, a prescription smoking cessation aid, which is a tobacco-based botanical medical product for use as a smoking cessation therapy. 22nd Century Group, Inc. is based in Williamsville, New York.
|